Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xenon ( (XENE) ) just unveiled an update.
Xenon Pharmaceuticals announced that it will present long-term data on its drug azetukalner at the American Academy of Neurology Annual Meeting in 2025. The data from the X-TOLE open-label extension study shows sustained reduction in seizure frequency and impressive seizure freedom rates in patients with focal onset seizures, suggesting long-term efficacy and tolerability. The company will also present findings on the mental health burdens of epilepsy and the efficacy of azetukalner across different seizure subtypes, potentially enhancing its positioning in the epilepsy treatment market.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel and highly potent Kv7 potassium channel opener, is their most advanced product in late-stage clinical development for multiple indications.
YTD Price Performance: -23.55%
Average Trading Volume: 478,757
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.35B
For detailed information about XENE stock, go to TipRanks’ Stock Analysis page.